Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secondary Cytoreductive Surgery in Platinum-Resistant Ovarian Cancer
NCT04795596Phase 3Withdrawn
- Sponsor
- Menoufia University
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Menoufia University. Primary endpoint: Progression-Free Survival at 6 months. Planned start Apr 2021; status: withdrawn.
Beyond the preview
Go deeper on NCT04795596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04795596.